Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice

• Main Authors: Henry L. Blanton (Author), Melissa C. McHann (Author), Haley De Selle (Author), Canice Lei Dancel (Author), Jose-Luis Redondo (Author), Deborah Molehin (Author), Nadezhda A. German (Author), Scott Trasti (Author), Kevin Pruitt (Author), Isabel Castro-Piedras (Author), Josée Guindon (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cannabinoid-based therapies are increasingly being used by cancer patients to treat chemotherapy-induced nausea and vomiting. Recently, cannabinoids have gained increased attention for their effects on cancer growth. Indeed, the effect of CB2 (JWH-015, JWH-133) agonists on breast cancer models have...